GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jafron Biomedical Co Ltd (SZSE:300529) » Definitions » Gross Profit

Jafron Biomedical Co (SZSE:300529) Gross Profit : ¥1,664 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Jafron Biomedical Co Gross Profit?

Jafron Biomedical Co's gross profit for the three months ended in Mar. 2024 was ¥586 Mil. Jafron Biomedical Co's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1,664 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Jafron Biomedical Co's gross profit for the three months ended in Mar. 2024 was ¥586 Mil. Jafron Biomedical Co's Revenue for the three months ended in Mar. 2024 was ¥744 Mil. Therefore, Jafron Biomedical Co's Gross Margin % for the quarter that ended in Mar. 2024 was 78.68%.

Jafron Biomedical Co had a gross margin of 78.68% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Jafron Biomedical Co was 86.21%. The lowest was 79.44%. And the median was 84.64%.

Warning Sign:

Jafron Biomedical Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -1.2%.


Jafron Biomedical Co Gross Profit Historical Data

The historical data trend for Jafron Biomedical Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jafron Biomedical Co Gross Profit Chart

Jafron Biomedical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,234.42 1,662.82 2,273.39 2,051.33 1,538.36

Jafron Biomedical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 460.45 354.83 383.35 339.73 585.68

Competitive Comparison of Jafron Biomedical Co's Gross Profit

For the Medical Devices subindustry, Jafron Biomedical Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jafron Biomedical Co's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Jafron Biomedical Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where Jafron Biomedical Co's Gross Profit falls into.



Jafron Biomedical Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Jafron Biomedical Co's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=1922.348 - 383.984
=1,538

Jafron Biomedical Co's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=744.337 - 158.658
=586

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,664 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Jafron Biomedical Co's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=586 / 744.337
=78.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Jafron Biomedical Co  (SZSE:300529) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Jafron Biomedical Co had a gross margin of 78.68% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Jafron Biomedical Co Gross Profit Related Terms

Thank you for viewing the detailed overview of Jafron Biomedical Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Jafron Biomedical Co (SZSE:300529) Business Description

Traded in Other Exchanges
N/A
Address
No. 98, Science and Technology 6th Road, High-tech Zone, Guangdong Province, Zhuhai, CHN, 519085
Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.
Executives
Li Feng Director
He Xiao Lian Executives
Dong Fan Directors, Directors, and Executives
Ceng Kai Directors, executives
Tang Xian Min Directors, executives
Zhang Ming Yuan Secretary Dong
Fang Li Hua Supervisors
Zhang Guang Hai Directors, executives
Li De Zhi Executives
Lu Shao Zhang Executives

Jafron Biomedical Co (SZSE:300529) Headlines

No Headlines